Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Follow-up in soft tissue sarcomas

Follow-up in soft tissue sarcomas The strategy for the follow-up of soft tissue sarcomas (STS) after therapy is tailored to the individual risk of recurrence and based on efficient rather than sophisticated methods of observation. Along with advances in the treatment of sarcomas, earlier detection of a less advanced and resectable recurrent disease (local or metastasis—especially to the lungs) can prolong patient survival. Since the majority of STS relapses occur within 5 years after treatment (approximately 80 % of metastases to the lung and close to 70 % of local recurrences within the first 2–3 years), in the period between 2 and 3 years after treatment, it is mandatory to follow-up patients every 3 months and perform careful history and physical examination (especially scars after surgery of the primary site) and a chest X-ray. There is no reason to perform other studies in asymptomatic patients (unless the patient reports symptoms). In case of retroperitoneal or intraperitoneal STS (including gastrointestinal stromal tumor), contrast-enhanced computed tomography of the abdomen and pelvis is recommended as the follow-up modality of choice. In this paper we outline the current recommendations for the follow-up strategy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Follow-up in soft tissue sarcomas

Download PDF
5 pages

Loading next page...
 
/lp/springer-journals/follow-up-in-soft-tissue-sarcomas-Xbyw1or74o
Publisher
Springer Journals
Copyright
Copyright © 2014 by The Author(s)
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-014-0146-8
Publisher site
See Article on Publisher Site

Abstract

The strategy for the follow-up of soft tissue sarcomas (STS) after therapy is tailored to the individual risk of recurrence and based on efficient rather than sophisticated methods of observation. Along with advances in the treatment of sarcomas, earlier detection of a less advanced and resectable recurrent disease (local or metastasis—especially to the lungs) can prolong patient survival. Since the majority of STS relapses occur within 5 years after treatment (approximately 80 % of metastases to the lung and close to 70 % of local recurrences within the first 2–3 years), in the period between 2 and 3 years after treatment, it is mandatory to follow-up patients every 3 months and perform careful history and physical examination (especially scars after surgery of the primary site) and a chest X-ray. There is no reason to perform other studies in asymptomatic patients (unless the patient reports symptoms). In case of retroperitoneal or intraperitoneal STS (including gastrointestinal stromal tumor), contrast-enhanced computed tomography of the abdomen and pelvis is recommended as the follow-up modality of choice. In this paper we outline the current recommendations for the follow-up strategy.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jun 13, 2014

References

  • Surveillance in patients with sarcoma of the extremities
    Cool, P; Grimer, R; Rees, R.
  • Guidelines for the management of soft tissue sarcomas
    Grimer, R; Judson, I; Peake, D; Seddon, B.
  • Follow-up after primary treatment of soft tissue sarcoma of extremities: impact of frequency of follow-up imaging on disease-specific survival
    Chou, YS; Liu, CY; Chen, WM; Chen, TH; Chen, PC; Wu, HT; Chiou, HJ; Shiau, CY; Wu, YC; Liu, CL; Chao, TC; Tzeng, CH; Yen, CC.
  • Soft tissue sarcomas in adult patients –guidelines for diagnosis and treatment.
    Ruka, W; Rutkowski, P; Krzakowski, M; Grzesiakowska, U; Ptaszyński, K; Jeziorski, A; Polkowski, W; Ryś, J; Słuszniak, J; Dziewirski, W; Morysiński, T; Świtaj, T; Bębenek, M; Siedlecki, JA; Limon, J; Nowecki, ZI.
  • The surgical treatment of lung metastases. The European organization for research and treatment of cancer—soft tissue and bone sarcoma group study of 255 patients
    Van Geel, AN; Pastorini, U; Jauch, KW; Judson, IR; van Coevorden, F; Buesa, JM; Nielsen, OS; Boudinet, A; Tursz, T; Schmitz, PIM.
  • The follow-up of adult soft tissue sarcomas
    Patel, SR; Zagars, GK; Pisters, PWT.
  • Five-years survival after pulmonary metastasectomy for adult soft tissue sarcoma
    Casson, AG; Putnam, JB; Natarajan, G; Johnston, DA; Mountain, C; McMurtrey, M; Roth, JA.
  • Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma
    Gadd, MA; Casper, ES; Woodruff, JM
  • Primary extremity sarcoma: What is the appropriate follow-up?
    Whooley, BP; Gibbs, JF; Mooney, MM
  • Effective follow-up strategies in soft tissue sarcoma
    Whooley, BP; Mooney, MM; Gibbs, JF; Kraybill, WG.
  • Soft-tissue sarcoma: MR imaging vs sonography for detection of local recurrence after surgery
    Choi, H; Varma, DG; Fornage, BD; Kim, EE; Johnston, DA.
  • Soft tissue sarcomas: ultrasonographic evaluation of local recurrences
    Arya, S; Nagarkatti, DG; Dudhat, SB; Nadkarni, KS; Joshi, MS; Shinde, SR.
  • Ultrasonography is superior to computed tomography and magnetic resonance imaging in determining superficial resection margins of malignant chest wall tumors
    Briccoli, A; Galletti, S; Salone, M; Morganti, A; Pelotti, P; Rocca, M.
  • Detection of local recurrences of limb soft tissue sarcomas: Is magnetic resonance imaging (MRI) relevant?
    Labarre, D; Aziza, R; Filleron, T; Delannes, M; Delaunay, F; Marques, B; Ferron, G; Chevreau, C.
  • MR imaging in the follow-up of malignant and aggressive soft-tissue tumors: results of 511 examinations
    Vanel, D; Shapeero, LG; Baere, T
  • Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
  • Follow-up is valuable and effective: true, true and unrelated?
    Brennan, MF.
  • Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up
    Casali, PG; Jost, L; Reichardt, P
  • Recommendations for diagnostics and therapy of gastrointestinal stromal tumors (GIST) in 2010
    Rutkowski, P; Kulig, J; Krzakowski, M
  • Follow-up after primary treatment of soft tissue sarcoma: a survey of current practice in the United Kingdom
    Gerrand, CH; Billingham, LJ; Woll, PJ; Grimer, RJ.
  • How surgeon age affects surveillance strategies for extremity soft tissue sarcoma patients after potentially curative treatment
    Sakata, K; Beitler, AL; Gibbs, JF; Kraybill, WG; Virgo, KS; Johnson, FE.
  • Does intensity of surveillance affect survival after surgery for sarcomas? Results of a randomized noninferiority trial
    Puri, A; Gulia, A; Hawaldar, R; Ranganathan, P; Badwe, RA.
  • Clinical utility of the new American Joint Committee on cancer staging system for gastrointestinal stromal tumors: Current overall survival after primary tumor resection
    Rutkowski, P; Wozniak, A; Dębiec-Rychter, M; Kąkol, M; Dziewirski, W; Zdzienicki, M; Ptaszynski, K; Jurkowska, M; Limon, J; Siedlecki, JA.
  • Towards global consensus in the treatment of gastrointestinal stromal tumor
    Reichardt, P; Blay, JY; Mehren, M.
  • One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial
    Joensuu, H.; Eriksson, M.; Sundby Hall, K; Hartmann, JT; Pink, D; Schütte, J; Ramadori, G; Hohenberger, P; Duyster, J; Al-Batran, SE; Schlemmer, M; Bauer, S; Wardelmann, E; Sarlomo-Rikala, M; Nilsson, B; Sihto, H; Monge, OR; Bono, P; Kallio, R; Vehtari, A; Leinonen, M; Alvegård, T; Reichardt, P.
  • Costs of follow-up after potentially curative treatment for extremity soft-tissue sarcoma
    Goel, A; Christy, M; Virgo, K; Kraybill, W; Johnson, F.